Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2021, with a specific reporting date of October 15, 2021. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
This filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics for the company. The only financial data provided relates to specific share transactions:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Price: $38.7117 per ADS.
- Transaction Volume: Total of 3,765.959 ADSs acquired across four executives.
- Transaction Date: October 13, 2021.
- Exchange: New York Stock Exchange (XNYS).
Material Changes
The filing reports no material changes to the company's financial position or operations. It solely documents the acquisition of ADSs by four executives following the re-investment of dividends paid to shareholders on October 7, 2021. No comparative period data is provided as this is a regulatory disclosure of specific transactions rather than a periodic financial report.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. The document is strictly a compliance notification of share acquisitions.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ADSs via dividend re-investment, not open market purchases or sales.
- Executives Involved:
- Dr. H. Barron (Chief Scientific Officer and President, R&D): 1,274.757 ADSs.
- Mr. J. Ford (SVP & General Counsel): 124.958 ADSs.
- Mr. B. McNamara (CEO, GSK Consumer Healthcare): 1,772.101 ADSs.
- Ms. K. Terrell (Chief Digital & Technology Officer): 594.143 ADSs.
- Dividend Context: The transactions were triggered by dividends paid on October 7, 2021.
- Financial Data Limitation: Investors should refer to GSK's Form 20-F or quarterly reports for comprehensive financial performance data, as this filing provides none.